Aventis/DuPont
Executive Summary
Talks discontinued regarding sale of Aventis' Romainville, France R&D facility to DuPont. The negotiation, which was initiated in March, would have included the sale of eight Aventis products and the transfer of a 300-person sales force to DuPont. Former DuPont Pharmaceuticals CEO Kurt Landgraf touted the agreement as a means for DuPont to benefit from consolidation without pursuing a merger of its own (1"The Pink Sheet" March 13, p. 19). Landgraf was replaced by Nicholas Teti in May. Aventis said it will seek a new buyer for the plant